All In Biotech

Drug Trial Radar · NCT00696475

Diazoxide Choline in Hypertriglyceridemia

A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects

Last checked: Nov 19, 2026Latest source record: Nov 8, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Planned (sponsor's estimate)

Start

Jun 2008

Primary completion

Jan 2009

Study completion Mar 2009

Sponsor

Lead sponsor
Essentialis, Inc.Industry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Jun 12, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypertriglyceridemia affects 30% of the population in the US. Very high level of triglycerides is a known risk factor for pancreatitis. In addition, studies have shown that hypertriglyceridemia is an independent risk factor for cardiovascular disease. Diazoxide is a KATP channel opener. It has been approved by the FDA as an oral suspension for the treatment of hyperinsulinemic hypoglycemic conditions and as an IV solution for malignant hypertension. Preclinical and clinical studies suggest that diazoxide can be a potential therapeutic agent for hypertriglyceridemia. Diazoxide choline is a novel, highly crystalline proprietary salt of diazoxide, which has been formulated as a controlled-release tablet suitable for once per day dosing. This current study is designed to assess the effect of diazoxide choline on triglycerides in subjects with baseline hypertriglyceridemia. In addition, the effects on other lipid parameters, glucose and insulin, body weight as well as the safety and tolerability of diazoxide choline will be assessed.

Conditions

  • Hypertriglyceridemia

Interventions

  • Diazoxide cholineDrug

  • Diazoxide cholineDrug

  • Diazoxide cholineDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the effect on triglycerides of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjectsTime frame: 8 weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • National Research Institute

    Los Angeles, California

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Allied Research International/Cetero Research

    Miami Gardens, Florida

  • Meridien Research

    Tampa, Florida

  • Midwest Institute for Clinical Research

    Indianapolis, Indiana

  • L-MARC Research Center

    Louisville, Kentucky

  • St. Luke's Lipid and Diabetes Research Center

    Kansas City, Missouri

  • Piedmont Medical Research Associates

    Winston-Salem, North Carolina

  • Metabolic and Atherosclerosis Research Center (MARC)

    Cincinnati, Ohio

  • Sterling Research Group, Ltd

    Cincinnati, Ohio

  • Frederick C. Smith Clinic

    Marion, Ohio

  • TriCities Medical Research

    Bristol, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.